People who think that rejuvenation therapies are only for the rich are not paying attention.
Look at first generation senolytic drug candidates that clear ~25% of senescent cells in mice, varying by tissue type. These vary from $100 per dose, for things like dasatinib plus quercetin, to a few thousand dollars per dose where you need a biotech company to one-off synthesize it for you, such as foxo4-dri. One dose is needed every few years - more than that won't help further.
The story will be the same for glucosepane cross-link breakers.
The trend in this type of technology is towards engineered small molecule / enzyme / peptide / etc that will cost next to nothing a decade after it is introduced, and can in any case be manufactured to order in China and shipped in if the patent holder decides to try charging monopoly rates. Alternatively, gene and cell therapies that can be mass produced, all the complexity baked into that manufacture, and then administered by a bored clinician. The cost will be similar to present day biologics, which are largely in the $1-10k/dose range. Again all of these treatments will be once-every-few-years, not any more frequently. That is the point of damage repair as a strategy - you only need to do it as often as the damage builds up. There is no point in doing it any more often.
Look at first generation senolytic drug candidates that clear ~25% of senescent cells in mice, varying by tissue type. These vary from $100 per dose, for things like dasatinib plus quercetin, to a few thousand dollars per dose where you need a biotech company to one-off synthesize it for you, such as foxo4-dri. One dose is needed every few years - more than that won't help further.
The story will be the same for glucosepane cross-link breakers.
The trend in this type of technology is towards engineered small molecule / enzyme / peptide / etc that will cost next to nothing a decade after it is introduced, and can in any case be manufactured to order in China and shipped in if the patent holder decides to try charging monopoly rates. Alternatively, gene and cell therapies that can be mass produced, all the complexity baked into that manufacture, and then administered by a bored clinician. The cost will be similar to present day biologics, which are largely in the $1-10k/dose range. Again all of these treatments will be once-every-few-years, not any more frequently. That is the point of damage repair as a strategy - you only need to do it as often as the damage builds up. There is no point in doing it any more often.